Literature DB >> 10100710

The prognostic significance of angiogenesis in epithelial ovarian carcinoma.

A A Alvarez1, H R Krigman, R S Whitaker, R K Dodge, G C Rodriguez.   

Abstract

The molecular biology underlying the metastatic process in ovarian carcinoma remains poorly understood. For other neoplasms, the induction of angiogenesis by malignant cells has been shown to play a pivotal role in the process of tumor proliferation and metastasis. The purpose of this study was to characterize the degree of angiogenesis in epithelial ovarian malignancies and to determine whether the degree of neovascularization has prognostic significance for survival. Tissue sections obtained from 88 ovarian cancer patients were examined immunohistochemically for angiogenesis after staining with anti-human endothelial cell antibodies to von Willebrand factor and CD31. Light microscopy was performed, and individual microvessel counts were quantified at high power (x400). A chart review was completed, collating data regarding age, stage, grade, status of disease, and survival. Statistical exploratory methods were used to find potentially useful prognostic cutpoints for marker values of angiogenesis. Of the total 88 patients, tissue microvessel counts from 85 were evaluated via antibodies to von Willebrand factor and 87 for CD31. Overall, median survival was 2.7 years in women with cancers containing high microvessel counts versus 7.9 years in those with low microvessel counts (P = 0.03). A low microvessel count was associated with better 5-year survival in both early stage (I and II) and advanced stage (III and IV) disease. Our data suggest that the degree of neovascularization may have prognostic significance in epithelial ovarian carcinoma, especially for women with early-stage disease. In this group of women, the degree of angiogenesis may allow the selection of women at high risk for recurrence who may benefit from aggressive adjuvant therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10100710

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  51 in total

1.  Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

Authors:  S John Weroha; Ann L Oberg; Katie L Allen Ziegler; Shaker R Dakhilm; Kendrith M Rowland; Lynn C Hartmann; Dennis F Moore; Gary L Keeney; Prema P Peethambaram; Paul Haluska
Journal:  Gynecol Oncol       Date:  2011-04-22       Impact factor: 5.482

Review 2.  Targeting angiogenesis in gynecologic cancers.

Authors:  Behrouz Zand; Robert L Coleman; Anil K Sood
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

3.  Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

Authors:  Jason A Konner; Diana M Grabon; Scott R Gerst; Alexia Iasonos; Howard Thaler; Sandra D Pezzulli; Paul J Sabbatini; Katherine M Bell-McGuinn; William P Tew; Martee L Hensley; David R Spriggs; Carol A Aghajanian
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

4.  Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Authors:  Ernest S Han; Robert A Burger; Kathleen M Darcy; Michael W Sill; Leslie M Randall; Dana Chase; Basmina Parmakhtiar; Bradley J Monk; Benjamin E Greer; Patrick Connelly; Koen Degeest; John P Fruehauf
Journal:  Gynecol Oncol       Date:  2010-09-25       Impact factor: 5.482

5.  Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Bradley J Monk; Joan L Walker; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Gini F Fleming; Peter C Lim; Stephen C Rubin; Noriyuki Katsumata; Sharon X Liang
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

Review 6.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

7.  Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance.

Authors:  S Krishna Priya; Kishore Kumar; K R Hiran; M R Bindhu; Rohit P Nagare; D K Vijaykumar; T S Ganesan
Journal:  Int J Clin Oncol       Date:  2016-08-27       Impact factor: 3.402

8.  Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.

Authors:  Beverly A Teicher; Krishna Menon; Enrique Alvarez; Chuan Shih; Margaret M Faul
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

9.  In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.

Authors:  Martin Pölcher; Christian Rudlowski; Nicolaus Friedrichs; Marieke Mielich; Tobias Höller; Mathias Wolfgarten; Kirsten Kübler; Reinhard Büttner; Walther Kuhn; Michael Braun
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

10.  A current review of targeted therapeutics for ovarian cancer.

Authors:  Susana M Campos; Sue Ghosh
Journal:  J Oncol       Date:  2010-01-03       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.